A real-world cohort study examined neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as prognostic markers in patients receiving anti-EGFR therapy. (Colorectal Dis)
Inflammation markers predict outcomes in RAS/BRAF wild-type mCRC on anti-EGFR therapy
The CRC Digest